INSPIRE MEDICAL SYSTEMS INC
INSPNYSETrading Snapshot
- Day Range
- $57.68 – $59.14
- 52-Week Range
- $38.91 – $147.03
- Volume
- $1.88B
- Avg Volume
- $1.49B
- Shares Outstanding
- 28.9M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $912M
- Last Q Revenue
- $201M
- P/E Ratio
- 12.5
- P/S Ratio
- 1.9x
- EPS (TTM)
- $4.68
- Dividend Yield
- 0.00%
Why Investors Own INSP
- ✓High-growth profile — revenue up +1.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INSPIRE MEDICAL SYSTEMS INC
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Inspire Medical Systems, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Inspire Medical Systems, Inc.
Oppenheimer Upgrades Inspire Medical Systems (INSP)
JP Morgan Maintains Neutral on Inspire Medical Systems, Raises Price Target to $60
JP Morgan analyst Robbie Marcus maintains Inspire Medical Systems (NYSE:INSP) with a Neutral and raises the price target from $54 to $60.
Mizuho Maintains Outperform on Inspire Medical Systems, Raises Price Target to $65
Mizuho analyst Anthony Petrone maintains Inspire Medical Systems (NYSE:INSP) with a Outperform and raises the price target from $55 to $65.
Oppenheimer Upgrades Inspire Medical Systems to Outperform, Announces $85 Price Target
Oppenheimer analyst Suraj Kalia upgrades Inspire Medical Systems (NYSE:INSP) from Perform to Outperform and announces $85 price target.
Truist Securities Reiterates Hold on Inspire Medical Systems, Raises Price Target to $62
Truist Securities analyst Richard Newitter reiterates Inspire Medical Systems (NYSE:INSP) with a Hold and raises the price target from $54 to $62.